Heron Therapeutics Inc (HRTX) : Vhcp Management Ii added new position in Heron Therapeutics Inc during the most recent quarter end. The investment management firm now holds 405,901 shares of Heron Therapeutics Inc which is valued at $6.6 Million , the company said in a statement filed on May 13, 2016 with the SEC.Heron Therapeutics Inc makes up approximately 4.25% of Vhcp Management Ii’s portfolio.
Other Hedge Funds, Including , Geode Capital Management boosted its stake in HRTX in the latest quarter, The investment management firm added 2,908 additional shares and now holds a total of 207,789 shares of Heron Therapeutics Inc which is valued at $3.4 Million. Trexquant Investment Lp sold out all of its stake in HRTX during the most recent quarter. The investment firm sold 11,072 shares of HRTX which is valued $180,806.Nationwide Fund Advisors reduced its stake in HRTX by selling 405 shares or 2.11% in the most recent quarter. The Hedge Fund company now holds 18,810 shares of HRTX which is valued at $316,760.Russell Frank Co reduced its stake in HRTX by selling 23,828 shares or 48.8% in the most recent quarter. The Hedge Fund company now holds 25,002 shares of HRTX which is valued at $536,043. Quantbot Technologies Lp sold out all of its stake in HRTX during the most recent quarter. The investment firm sold 170 shares of HRTX which is valued $3,645.
Heron Therapeutics Inc opened for trading at $20.74 and hit $21.085 on the upside on Wednesday, eventually ending the session at $20.57, with a gain of 0.19% or 0.04 points. The heightened volatility saw the trading volume jump to 4,07,359 shares. Company has a market cap of $754 M.
Many Wall Street Analysts have commented on Heron Therapeutics Inc. Heron Therapeutics Inc was Initiated by Cantor Fitzgerald to “Buy” on May 3, 2016.
Heron Therapeutics Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company’s product candidate SUSTOL (granisetron injection extended release) is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Company’s product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort or eliminate the drawbacks of current therapies. The Company’s other product candidates include HTX-019 for CINV which is in Preclinical state; HTX-011 for Post-operative pain management which is in Phase I trials and HTX-003 for chronic pain management which is in Preclinical state.